llumina and Roche have signed a 15-year, non-exclusive collaboration agreement designed to realize next-generation sequencing's potential to transform cancer risk prediction, detection, diagnosis, treatment, and monitoring . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge